Carboplatin

Retinoblastoma, advanced Thymoma, Advance Directives + 20 more
Treatment
3 FDA approvals
20 Active Studies for Carboplatin

What is Carboplatin

CarboplatinThe Generic name of this drug
Treatment SummaryCarboplatin is a chemotherapy drug used to treat advanced ovarian cancer. It was first tested in 1982 and was approved by the FDA in 1989. Carboplatin is an analog of cisplatin, but it has fewer side effects such as kidney damage and vomiting.
Carboplatinis the brand name
image of different drug pills on a surface
Carboplatin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Carboplatin
Carboplatin
2004
69

Approved as Treatment by the FDA

Carboplatin, also called Carboplatin, is approved by the FDA for 3 uses including Advanced Ovarian Carcinoma and initial treatment .
Advanced Ovarian Carcinoma
Used to treat Advanced Ovarian Carcinoma in combination with Carboplatin
initial treatment
Used to treat initial treatment in combination with Carboplatin
Ovarian Neoplasms
Used to treat Advanced Ovarian Carcinoma in combination with Carboplatin

Effectiveness

How Carboplatin Affects PatientsCarboplatin is a drug used to fight certain types of cancer, particularly ovarian cancer. It takes a few weeks for the drug to become effective, and care must be taken to ensure patients are taking the correct dosage. Patients should be aware that the drug could cause bone marrow suppression and anemia.
How Carboplatin works in the bodyCarboplatin works by directly damaging DNA. It attaches alkyl groups to the nucleotides in the genetic material, causing it to break when repair enzymes attempt to fix it. Additionally, it can form links between two different strands of DNA, preventing them from separating for transcription or replication. Lastly, carboplatin can cause mutations in the DNA.

When to interrupt dosage

The suggested dosage of Carboplatin is based on the diagnosed affliction, including Pharmacotherapy, Carcinoma, Neuroendocrine and advanced Testicular cancer. The measure is contingent upon the technique of issuance, as specified in the table beneath.
Condition
Dosage
Administration
Metastatic Breast Cancer
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Ovarian Neoplasms
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
melanoma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Recurrence
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Palliative Treatment
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Testicular Neoplasms
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Hodgkin Disease
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Esophageal Neoplasms
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Pharmacotherapy
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Endometrial Neoplasms
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Uterine Cervical Neoplasms
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Carcinoma, Non-Small-Cell Lung
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Head and Neck Neoplasms
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
initial treatment
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Retinoblastoma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
conditioning regimens for allogeneic stem cell transplantation therapy
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Lymphoma, Non-Hodgkin
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Carboplatin Contraindications
Condition
Risk Level
Notes
Hemorrhage
Do Not Combine
Bone Marrow
Do Not Combine
There are 20 known major drug interactions with Carboplatin.
Common Carboplatin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with Acteoside.
Carboplatin Toxicity & Overdose RiskSomeone who has overdosed on carboplatin may suffer from low white blood cell levels and liver damage. Treatment should involve relieving symptoms and providing supportive care, such as delaying the next dose.
image of a doctor in a lab doing drug, clinical research

Carboplatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Carboplatin?

148 active clinical trials are currently assessing the potential of Carboplatin to treat Metastatic Breast Cancer, Advance Directives and conditioning regimens for Allogeneic Stem Cell Transplantation Therapy.
Condition
Clinical Trials
Trial Phases
conditioning regimens for allogeneic stem cell transplantation therapy
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Esophageal Neoplasms
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
melanoma
0 Actively Recruiting
Recurrence
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Palliative Treatment
1 Actively Recruiting
Not Applicable
Carcinoma, Non-Small-Cell Lung
27 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
initial treatment
0 Actively Recruiting
Lymphoma, Non-Hodgkin
0 Actively Recruiting
Ovarian Neoplasms
0 Actively Recruiting
Malignant Mesothelioma
16 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable
Testicular Neoplasms
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Retinoblastoma
6 Actively Recruiting
Phase 2, Not Applicable, Phase 1
Endometrial Neoplasms
0 Actively Recruiting
Head and Neck Neoplasms
0 Actively Recruiting
advanced Thymoma
0 Actively Recruiting
Hodgkin Disease
2 Actively Recruiting
Phase 2, Phase 1

Carboplatin Reviews: What are patients saying about Carboplatin?

5Patient Review
9/19/2009
Carboplatin for Non-Small Cell Lung Cancer
This drug was better than anticipated. I had no issues with nausea or tiredness, though resting was key. It took a bit longer to get my white blood cell count back up, but a shot of Neulasta helped out a lot.
5Patient Review
4/14/2010
Carboplatin for Cancer of the Ovary
I had eight doses of Taxol starting in 2007, and after a rising CA125, I've now had four more doses. I had a mild allergic reaction to the fourth dose, so I'll be premedicating for the fifth.
5Patient Review
1/9/2009
Carboplatin for Cancer of the Ovary
5Patient Review
4/14/2009
Carboplatin for Cancer of the Ovary
5Patient Review
4/9/2014
Carboplatin for Cancer of the Ovary
I was cancer-free within weeks of starting this treatment, and I couldn't have been more pleased with how easy it was to take.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about carboplatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of chemo is carboplatin?

"Carboplatin is similar to cisplatin but has a platinum atom complexed with glucose.

Carboplatin is a drug that is used to treat cancer. It is classified as an alkylating agent, which are drugs that are used to kill cancer cells. Carboplatin is similar to cisplatin, but it has a platinum atom complexed with glucose."

Answered by AI

Is carboplatin a strong chemo?

"If you experience numbness or tingling, tell your doctor so they can monitor the symptoms. Carboplatin may cause severe tingling in some cases and stopping treatment may be necessary."

Answered by AI

What are the common side effects of carboplatin?

"The symptoms of the illness include nausea, vomiting, diarrhea, constipation, sores in the mouth and throat, pain, burning, or tingling in the hands or feet."

Answered by AI

Is carboplatin an immunotherapy or chemo?

"The standard treatment for this type of cancer generally includes the use of the chemotherapy drugs Paclitaxel and carboplatin."

Answered by AI

Clinical Trials for Carboplatin

Have you considered Carboplatin clinical trials? We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Have you considered Carboplatin clinical trials? We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Have you considered Carboplatin clinical trials? We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top